A phase I study of cabozantinib (XL184) in patients with renal cell cancer

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1603-1608

  Choueiri, Toni K ^a   Pal, S K ^b   McDermott, D F ^a,c   Morrissey, S ^a   Ferguson, K C ^d   Holland, J ^d   Kaelin, W G ^a   Dutcher, J P ^e,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d EXELIXIS INC   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f Cancer Research Foundation   (United States)

Author keywords

C Met; Clinical trial; Receptor tyrosine kinase; Renal cancer; Vegfr 2

Indexed keywords

CABOZANTINIB; ROSIGLITAZONE; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MALE; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; KIDNEY METASTASIS; TREATMENT OUTCOME; CARCINOMA, RENAL CELL; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; KIDNEY NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TUMOR VOLUME;

ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84905175125     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu184     Document Type: Article

References (30)

1. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011; 10: 2298-2308.
2. Kurzrock R, Sherman SI, Ball DW et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011; 29: 2660-2666.
3. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013; 31: 412-419.
4. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 2009; 9: 785-793.
5. Rini BI. Metastatic renal cell carcinoma: many treatment options, one patient. J Clin Oncol 2009; 27: 3225-3234.
6. Gibney GT, Aziz SA, Camp RL et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013; 24: 343-349.
7. Bommi-Reddy A, Almeciga I, Sawyer J et al. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 2008; 105: 16484-16489.
8. Heng DY, Xie W, Bjarnason GA et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol 2012; 23: 1549-1555.
9. Shojaei F, Lee JH, Simmons BH et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010; 70: 10090-10100.
10. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-221. Erratum in: Nat Rev Clin Oncol 2011; 8: 316.
11. Sennino B, Ishiguro-Oonuma T, Wei Y et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270-287.
12. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
13. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14: 141-148.
14. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
15. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alpha in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
16. Motzer RJ, Hutson TE, Cella D et al. Pazopanib versus sunitinib in metastatic renalcell carcinoma. N Engl J Med 2013; 369: 722-731.
17. Rini RJ, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet 2011; 378: 1931-1939.
18. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid carcinoma. J Clin Oncol 2013; 31: 3639-3646.
19. Smith MR, Sweeney C, Corn PG et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II non-randomized expansion study. J Clin Oncol 2014; in press.
20. Amato RJ, Flaherty AL, Stepankiw M. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin Genitourin Cancer 2012; 10: 26-31.
21. Bellmunt J, Trigo JM, Calvo E et al. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010; 11: 350-357.
22. Motzer RJ, Escudier B, Oudard S et al. RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
23. Motzer RJ, Porta C, Vogelzang NJ. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 286-296.
24. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-6249s.
25. Beuselinck B, Oudard S, Rixe O et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22: 794-800.
26. Aftab DT, McDonald DM. MET and VEGF: synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol 2011; 13: 703-709.
27. Nguyen HM, Ruppender N, Zhang X et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS ONE 2013; 8: e78881.
28. Dai J, Zhang H, Karatsinides A et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2014; 20: 617-630.
29. Tolaney SM, Nechushtan H, Berger R et al. Cabozantinib (XL184) in patients with metastatic breast cancer: results from a phase 2 randomized discontinuation trial. Cancer Res 2011; 71 (24): 3s.
30. Lee RJ, Saylor PJ, Michaelson MD et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013; 19: 3088-3094.